Status:

WITHDRAWN

Intradiscal Discogel® in Resistant Sciatica

Lead Sponsor:

Assistance Publique - Hôpitaux de Paris

Collaborating Sponsors:

Gelscom SAS

Conditions:

Herniated Disc

Sciatica

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Sciatica due to herniated disc is a major cause of disability in young adults. Surgery is the gold-standard and the only controlled treatment in case of failure of conservative treatment. Percutaneou...

Detailed Description

Since chymopapain was taken off the market in 2002, no percutaneous treatment has been proven to be a valuable alternative to surgical discectomy in herniated disk-related sciatica. Intradiscal inject...

Eligibility Criteria

Inclusion

  • Age ≥18
  • L5 or S1 sciatica due to a herniated disc demonstrated at a MRI performed at a maximum of 8 weeks prior to inclusion
  • Leg pain intensity superior to 40mm on a visual-analogue scale despite pain medication (patient with pain level of less than 40 mm and under morphinic treatment, morphine should be first replaced by level 2 medication).
  • Leg pain predominant over low back pain
  • Duration of sciatica of the current symptomatic episode: from 6 weeks to 40 weeks
  • Leg pain resistant to conservative treatment including at least two epidural steroid injections and at least one steroid injection under fluoroscopic guidance, during the current symptomatic episode
  • With or without sensitive deficit

Exclusion

  • \- Motricity index \< 3/5
  • Cauda equinal syndrome
  • Sequestered disc herniation visible at MRI
  • Calcified/ossified disc herniation visible at MRI
  • Intervertebral disc height narrowing \> 60%
  • Previous back surgery or percutaneous disc treatment at the same intervertebral level
  • Psychiatric status precluding patient evaluation
  • Pregnancy Any known or documented allergy to one of the components of the Discogel®

Key Trial Info

Start Date :

September 1 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 1 2018

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT02313350

Start Date

September 1 2017

End Date

January 1 2018

Last Update

June 18 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Department of Rheumatology, Lariboisière Hospital

Paris, France, 75010